• OUTLOOK ARENA
  • VIEWS ON NEWS
  • OCTOBER 25, 2004

GSK Consumer: Looking for rhythm

Performance summary
GSK Consumer Healthcare has reported 3% revenue growth during the third quarter ended September 2004. The company margins have improved significantly, thereby resulting in a 37% bottomline growth during the quarter. For the nine months ended September 2004, GSK has reported almost 8% revenue and around 7% bottomline growth.

(Rs m)3QCY033QCY04Change9mCY039mCY04Change
Net sales 2,281 2,350 3.0%6,0746,5527.9%
Expenditure 1,986 1,928 -2.9%5,0485,4467.9%
Operating Profit (EBDITA) 295 422 43.2% 1,026 1,106 7.8%
EBDITA margin (%)12.9%17.9% 16.9%16.9% 
Other income 47 30 -36.1%149104-30.2%
Interest (1) (3)85.7%5-20-476.9%
Depreciation 87 90 4.2%269268-0.2%
Profit before Tax 257 364 42.0% 900 961 6.7%
Tax 87 138 58.4%30935414.6%
Extraordinary income/(expense) (5) - - (22) - -
Profit after Tax 165 226 37.3% 569 607 6.6%
Net profit margin (%)7.2%9.6% 9.4%9.3% 
No. of Shares (m)45.445.4 45.445.4 
Diluted Earnings per share (Rs)*14.519.9 16.717.8 
Price to earnings ratio (x)     14.1  
*(annualised), CY = Calendar Year      

What is the company’s business?
GSK Consumer dominates the Rs 13 bn Indian malted beverage market with a significant 65% share (volume terms). Its white beverage brand ‘Horlicks’ has led to the market growth of this sector in India and contributes around 80% to the company’s revenues. The company’s other brands include ‘Boost’, ‘Viva’ and ‘Maltova’. The company also earns 4-5% fees by marketing products for SmithKline Beecham Asia Pvt. Ltd, the parent’s 100% subsidiary. The subsidiary has well known brands like ‘Aquafresh’ in oral care segment, ‘Eno’ and ‘Crocin’ in OTC portfolio. It recently also took up marketing of ‘Iodex’ for GSK Pharma.

What has driven performance in 3QCY05?
Sales:  The company is still unable to find a rhythm in its revenue trend. It still seems to be struggling and is yet to stabilise. Its revenue trend has been very volatile over the last seven quarters (see chart). GSK Consumer has provided no indication of how the malted beverage segment is growing, but we believe that the segment growth has slowed from its earlier average of 10% plus rate over the past decade.

Operating margins:  One of the key reasons for the company reporting strong bottomline growth is the significant improvement in operating margins (up 5% YoY). This has come about as a result of a dip in advertising expenses as a percentage of sales, as well as its raw material costs. Also, the third quarter of last year was abnormally bad for the company, thus showing a higher base improvement this year. During the nine month period however, GSK's margins have remained stable.

Cost break-up
as a % of net sales3QCY033QCY049mCY039mCY04
Stock3.3%1.5%-0.9%1.0%
RM34.5%32.4%36.0%35.0%
Finished goods1.2%1.3%1.0%1.0%
Staff cost10.0%10.2%10.5%10.8%
Advertising14.4%12.5%11.5%11.0%
Other exps.22.1%23.0%23.3%23.2%
Patent and trademark1.1%0.5%1.2%0.5%
Def. Rev. exps.0.5%0.5%0.6%0.6%
Total87.1%82.1%83.1%83.1%

What to expect?
The management has declared a second interim dividend of Rs 3.7 per share, taking the total interim dividend for 2004 to Rs 7 per share. The stock is trading at Rs 252, reflecting a P/E of 14.1 times annualised 9mCY04 earnings and market cap to sales of 1.3x. GSK Consumer has no doubt made some progress in reversing the decline in topline over the past few quarters. However, market conditions continue to be difficult for this single product company. A full fledged recovery in the company's fortunes still seems some time away and therefore, we view the company cautiously.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407